Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/29/2025

Post‑operative Management of Empagliflozin (Jardiance) and Semaglutide (Ozempic)

Empagliflozin (Jardiance) – Peri‑operative Ketoacidosis Risk and Restart Criteria

  • Empagliflozin increases the incidence of peri‑operative ketoacidosis to 1.02 cases per 1,000 surgeries versus 0.69 cases per 1,000 in non‑users (odds ratio 1.48); the risk persists into the postoperative recovery period. 1
  • Ketoacidosis associated with empagliflozin often presents euglycemically (blood glucose < 200 mg/dL), so reliance on glucose alone can miss the diagnosis; capillary or serum ketone measurement is required. 1
  • The drug stimulates hepatic ketone production and reduces renal ketone clearance, extending the window of ketoacidosis risk even after the medication is held pre‑operatively. 1
  • In patients with chronic heart failure, withholding empagliflozin for too long is linked to a three‑fold increase in peri‑operative mortality (≈9 % vs ≈3 %). Timely restart is therefore critical. 1
  • Same‑day discharge: Empagliflozin may be resumed 24–48 hours after surgery once the patient is eating and drinking normally and is adequately hydrated. 2
  • Hospitalized patients: Restart is permitted only when oral intake is normal and capillary ketones are < 0.6 mmol/L. 2
  • Discharge paperwork must contain sick‑day rules and explicit instructions to monitor for ketoacidosis symptoms even when glucose readings are normal. 2
  • Restarting empagliflozin solely on normal glucose values is unsafe; ketone testing must be performed before resumption. 2
  • Avoid excessive delay in restarting empagliflozin for heart‑failure patients, as postponement beyond 72 hours raises mortality risk. 2

Semaglutide (Ozempic) – Prolonged Gastric Emptying and Aspiration Risk

  • Semaglutide has an ≈1‑week half‑life; gastric emptying remains impaired for up to three half‑lives (≈3 weeks) after the last dose. 4
  • Even after ≥12 hours fasting and 10–14 days off the drug, 24.2 % of patients retain gastric contents versus 5.1 % of controls.
Group (fasted ≥12 h, off semaglutide 10–14 d) Residual Gastric Content
Semaglutide‑treated patients 24.2 %
Control patients 5.1 %

4

  • Case reports describe regurgitation and pulmonary aspiration in patients who stopped semaglutide only 4–6 days before surgery and fasted 18–20 hours, demonstrating that the drug’s effect outlasts standard holding periods. 5
  • Semaglutide should not be restarted at discharge; a minimum three‑week discontinuation is required before gastric emptying normalizes. 4
  • Prior to restarting, confirm that the patient tolerates oral intake without nausea, vomiting, or abdominal distention and shows no signs of delayed gastric emptying. 4
  • For weight‑loss indications, the full three‑week hold is mandatory. For diabetic patients, endocrinology consultation is advised to weigh glycemic benefit against ongoing aspiration risk. 4
  • Post‑operative monitoring must include assessment for nausea, vomiting, and aspiration pneumonia, as these may signal retained gastric contents. 5

Monitoring & Discharge Instructions (Both Agents)

  • Empagliflozin: Provide written “sick‑day” guidance, list ketoacidosis warning signs (e.g., nausea, abdominal pain, weakness), and specify a 24–48 hour post‑discharge restart window for most patients. 2
  • Semaglutide: Advise patients not to resume the medication at discharge; schedule a follow‑up with endocrinology (for diabetic patients) and instruct them to seek care if they develop gastrointestinal symptoms or signs of aspiration. 4

All facts are derived from cited sources and presented in English with generic patient descriptors.